Analgesia in the Critically Ill: Delivering, Monitoring, and Mastering the Art of Pain Control in the ICU

Dr Neeraj Manikath , claude.ai

"The patient lay sedated and apparently still — heart rate 112, blood pressure 158/96. The nurse noted she had not moved in six hours. Her family said she was 'comfortable.' Her CPOT score was 6. She was in agony. We had sedated the witness, not the pain."

— ICU Grand Rounds, Teaching Case, 2023

Introduction: The Invisible Epidemic Within Our ICUs

Pain is the most common, most undertreated, and most consequential symptom experienced by patients in the intensive care unit. Epidemiological data from the multinational EUROPATIENT study and subsequent registries consistently demonstrate that up to 80% of ICU patients experience moderate-to-severe pain, yet fewer than half receive adequate analgesia. The landmark ABCDEF Bundle trials and the 2018 PADIS (Pain, Agitation/Sedation, Delirium, Immobility, and Sleep) guidelines from the Society of Critical Care Medicine (SCCM) have fundamentally repositioned our thinking: pain, not sedation, must be addressed first.

The consequences of undertreated pain extend far beyond humanitarian concern. Poorly controlled pain activates the hypothalamic-pituitary-adrenal axis and the sympathoadrenal system, precipitating tachycardia, hypertension, increased myocardial oxygen demand, immune suppression, hypercoagulability, and impaired wound healing. Longitudinally, it contributes to post-intensive care syndrome (PICS), post-traumatic stress disorder (PTSD), and chronic pain syndromes — a burden that follows patients well beyond hospital discharge. Pain management in the ICU is not a comfort measure. It is a mortality-relevant intervention.

Pathophysiology: Only What You Must Know at the Bedside

Understanding why pain in the critically ill is biologically unique helps explain why standard analgesic approaches frequently fail.

Peripheral and central sensitisation occur rapidly in the setting of surgery, trauma, sepsis, and tissue ischaemia. Inflammatory mediators — prostaglandins, bradykinin, substance P, and cytokines — lower the firing threshold of nociceptors (peripheral sensitisation), while repeated nociceptive input leads to synaptic strengthening in the dorsal horn of the spinal cord (central sensitisation). The clinical result is allodynia (pain from non-painful stimuli) and hyperalgesia (exaggerated pain from noxious stimuli) — phenomena that render standard analgesic doses profoundly inadequate.

Critical illness additionally disrupts opioid pharmacokinetics in predictable ways: altered volume of distribution from capillary leak and third-spacing, impaired hepatic metabolism in multi-organ dysfunction, and reduced renal clearance of active metabolites. This creates a paradox — the sicker the patient, the less predictable the drug behaviour, and the more vigilant the monitoring must be.

Procedural pain deserves special mention. Studies using objective pain tools demonstrate that endotracheal suctioning, repositioning, wound care, and arteriovenous line insertion are among the most painful interventions in the ICU — more painful, for many patients, than the underlying illness. These "routine" care activities are a source of acute procedural pain that is systematically under-recognised and under-medicated.

🪙 Clinical Pearls

Pearl 1 — Sedation Masquerades as Comfort A deeply sedated patient who does not grimace is not a pain-free patient. Sedatives suppress the expression of pain, not the experience of it. The CPOT (Critical-care Pain Observation Tool) was specifically designed for non-communicative patients and captures facial expressions, body movements, muscle tension, and ventilator compliance — scoring ≥3 mandates analgesia regardless of apparent stillness.

Pearl 2 — Opioid Requirement is Diagnostic If a mechanically ventilated patient suddenly requires escalating fentanyl, before increasing the dose — pause. Consider pneumothorax, ET tube displacement, worsening pulmonary oedema, or peritoneal contamination. Pain behaviour is a clinical sign, not just a complaint.

Pearl 3 — The Hyperalgesia Trap Prolonged high-dose opioid infusions paradoxically increase pain sensitivity (opioid-induced hyperalgesia, OIH). A patient on Day 7 of morphine infusion who appears to require ever-increasing doses may actually be experiencing OIH — adding more morphine worsens the problem. Rotating to a different opioid (e.g., hydromorphone) or using low-dose ketamine is the solution.

Pearl 4 — Renal Failure and Morphine: A Hidden Killer Morphine-6-glucuronide (M6G) — the pharmacologically active metabolite of morphine — accumulates dangerously in renal failure, causing prolonged and life-threatening respiratory depression hours after the last dose. Fentanyl is the opioid of choice in AKI and CKD because it lacks active accumulating metabolites.

🦪 Oysters: Hidden Gems Most Clinicians Miss

Oyster 1 — The "Analgesia-First" or "Analgosedation" Paradigm Most intensivists still reach for propofol or midazolam first when a patient is agitated. The 2018 PADIS guidelines explicitly recommend analgesia-first sedation — treating pain before adding sedatives. In trials, this approach reduced sedative requirements, duration of mechanical ventilation, and ICU length of stay. Remifentanil-based analgosedation protocols have consistently outperformed traditional sedation approaches in this regard.

Oyster 2 — Ketamine: The Most Underused Analgesic in Critical Care Ketamine at sub-anaesthetic doses (0.1–0.5 mg/kg/hr as an infusion) provides excellent analgesia via NMDA receptor antagonism, preserves respiratory drive, reduces opioid consumption by 30–40%, and counteracts opioid-induced hyperalgesia. Yet it remains woefully underused. The 2022 KEAT (Ketamine Effectiveness as Analgesic Therapy) trial confirmed its opioid-sparing role without significant haemodynamic instability. It should be part of every intensivist's multimodal toolkit — particularly in post-surgical and trauma patients.

Oyster 3 — Regional Anaesthesia Has an ICU Role Thoracic epidural analgesia (TEA) in post-operative thoracic and abdominal surgical patients, transversus abdominis plane (TAP) blocks, and erector spinae plane (ESP) blocks are increasingly being deployed by anaesthesiologists and trained intensivists in the ICU. These techniques dramatically reduce opioid consumption, improve respiratory mechanics, and facilitate earlier extubation — yet are rarely considered once the patient has left the operating theatre.

Oyster 4 — The Circadian Rhythm of Pain Pain thresholds vary by time of day; most ICU patients report worst pain between 2:00 AM and 6:00 AM, during nursing procedures performed with reduced staffing. Timed analgesic adjustments — a concept borrowed from oncology palliative care — have not been formally studied in the ICU but represent an area of practice that master clinicians intuitively address.

Oyster 5 — Gabapentinoids for Neuropathic Pain Components Up to 30% of post-cardiac surgery, post-trauma, and prolonged ICU patients develop a neuropathic pain component characterised by burning, lancinating, or electric-shock quality pain. Opioids address this poorly. Low-dose gabapentin (100–300 mg BD, renally adjusted) or pregabalin is effective, but requires careful dose reduction for renal function and vigilance for respiratory depression when co-administered with opioids or benzodiazepines.

⚡ Clinical Hacks & Tips: What Master Intensivists Actually Do

Hack 1 — Build a Pain Round into Your Ward Round Structured morning pain assessment using the NRS (Numerical Rating Scale, 0–10) in communicative patients, or CPOT in non-communicative patients, should be as routine as reviewing ventilator settings. The target is NRS ≤3 or CPOT <3. Document this explicitly; it drives analgesic titration.

Hack 2 — Anticipate Procedural Pain: Pre-medicate, Don't React For every scheduled painful procedure (suctioning, chest physiotherapy, repositioning, line insertions, wound care), administer a short-acting opioid 15–30 minutes before the procedure. Fentanyl 25–50 mcg IV is ideal — rapid onset (2–3 min), predictable duration (30–45 min), easy to titrate.

Hack 3 — The Multimodal Analgesic Stack Avoid opioid monotherapy. Build a stack:

Layer	Drug	Typical Dose	Rationale
Base	Paracetamol (IV/oral)	1g q6h	Synergistic, opioid-sparing
Anti-inflammatory	IV ibuprofen or ketorolac	Ketorolac 15–30 mg q6h (max 5 days)	Use cautiously; avoid in AKI/GI bleed
Neuropathic	Gabapentin / Pregabalin	100–300 mg BD (renal-adjusted)	For neuropathic component
Procedural/acute	Fentanyl IV bolus	25–50 mcg PRN	Short-acting, titratable
Opioid maintenance	Morphine/Fentanyl infusion	Titrate to CPOT <3	Avoid morphine in AKI
NMDA adjunct	Ketamine infusion	0.1–0.3 mg/kg/hr	OIH prevention, opioid-sparing

Hack 3 — Delirium and Pain: Treat the Pain First Hyperactive delirium frequently coexists with undertreated pain. Before labelling a patient as delirious and administering antipsychotics or benzodiazepines, ensure adequate analgesia. Pain and delirium have a bidirectional, self-reinforcing relationship — breaking the pain cycle often dramatically reduces delirium severity.

Hack 4 — When Converting Between Opioids, Use Equianalgesic Tables and Reduce by 25–30% Incomplete cross-tolerance means that when rotating opioids, the equianalgesic dose will often exceed what is required. Standard practice is to calculate the equianalgesic dose, then reduce by 25–30% to avoid inadvertent overdose, and then titrate up as needed.

State-of-the-Art Updates: What Has Changed Practice

1. PADIS 2018 Guidelines — The Framework Shift The landmark 2018 SCCM PADIS guidelines formally established the priority order: Analgesia → Sedation → Delirium management. They endorsed CPOT and BPS (Behavioural Pain Scale) as validated tools for non-communicative, mechanically ventilated patients and made analgesia-first sedation a Grade 2B recommendation.

2. The SPICE III Trial (2019) This landmark RCT comparing early sedation with dexmedetomidine versus usual care demonstrated no mortality benefit for dexmedetomidine — but did confirm that lighter sedation is safe and associated with faster weaning. Dexmedetomidine remains valuable for its opioid-sparing, anti-shivering, and delirium-mitigating properties rather than as a primary analgesic.

3. Low-Dose Ketamine in Post-Operative ICU Patients Multiple RCTs and meta-analyses from 2020–2024 confirm that subanesthetic ketamine infusions (0.1–0.5 mg/kg/hr) reduce 24-hour opioid consumption by 30–40%, without significant increases in hallucinations or haemodynamic instability when used at these doses. This is now an ERAS (Enhanced Recovery After Surgery) recommendation in several major guidelines.

4. Point-of-Care Ultrasound-Guided Nerve Blocks in ICU The evolution of bedside POCUS has empowered trained intensivists to perform real-time guided nerve blocks (TAP, ESP, femoral, popliteal sciatic) at the bedside. A 2023 systematic review confirmed significant reductions in opioid requirements and improved respiratory mechanics with ESP blocks in rib fracture patients.

5. Non-Opioid Analgesics for Critically Ill — IV Lidocaine Intravenous lidocaine infusion (1.5 mg/kg bolus followed by 1.5 mg/kg/hr) has emerged as an evidence-based opioid-sparing analgesic in post-operative ICU patients, particularly following abdominal surgery. A 2022 Cochrane review confirmed significant opioid-sparing, anti-inflammatory, and prokinetic benefits. Cardiac monitoring is mandatory.

Diagnostic Nuances: Separating Good from Great Clinicians

The Non-Communicative Patient Intubated, sedated, or cognitively impaired patients cannot self-report pain — the gold standard. This is where most analgesic failures occur. Validated behavioural tools are mandatory:

CPOT (Critical-care Pain Observation Tool): Scores 4 domains — facial expression, body movements, muscle tension, ventilator compliance. Score ≥3 = significant pain. Validated in multiple ICU populations.
BPS (Behavioural Pain Scale): Similar construct; particularly validated in post-surgical patients.
Pupillometry: The Nociception Level (NOL) index, derived from multiparameter pupillometric analysis, is an emerging continuous, objective pain monitor — not yet standard of care, but increasingly available in tertiary centres.

The Delirious Patient Agitation and delirium are frequently misinterpreted as psychiatric in origin, when they are often pain-driven. Use CAM-ICU for delirium detection; if delirium coexists with high CPOT scores, treat pain first and reassess.

Signs of Opioid Toxicity in the Monitored ICU Patient

Respiratory rate <10 breaths/min in a spontaneously breathing patient
Miosis with reduced SpO2
Sudden improvement in agitation followed by reduced GCS
End-tidal CO2 rise on capnography (in monitored patients)

Withdrawal Mimicking Undertreated Pain Patients who have received opioids for ≥5–7 days are at risk for opioid withdrawal when weaning. Withdrawal presents with tachycardia, hypertension, diaphoresis, lacrimation, GI upset, and agitation — all of which can masquerade as undertreated pain and trigger unwarranted dose escalation. Planned, structured opioid weaning protocols (typically 10–20% dose reduction every 24–48 hours) prevent this.

Management Intricacies: Drugs, Doses, Timing, and Pitfalls

Opioids — The Backbone, Not the Whole House

Opioid	Onset IV	Duration	Key Points
Fentanyl	2–3 min	30–60 min	Drug of choice in AKI; no histamine release
Morphine	5–10 min	3–4 hr	Avoid in AKI (M6G accumulation); cheap, familiar
Hydromorphone	5 min	3–4 hr	5–7x potency of morphine; use in opioid-tolerant patients
Remifentanil	<1 min	5–10 min	Ultra-short; ideal for analgosedation protocols; context-insensitive
Methadone	10–15 min	24–36 hr	QTc prolongation risk; complex kinetics; use for opioid rotation/weaning

Non-Opioid Multimodal Agents — Never Optional

Paracetamol (IV): 1g q6h — the cornerstone of multimodal analgesia. Opioid-sparing effect of 20–30%. Safe in hepatically normal patients. Do not omit.
NSAIDs/Ketorolac: Significant opioid-sparing but contraindicated in AKI, GI haemorrhage, coagulopathy, and post-cardiac surgery. If using, limit to 5 days maximum.
Dexmedetomidine: Alpha-2 agonist with sedative and opioid-sparing properties. Particularly valuable post-extubation for analgo-sedation. Does not cause respiratory depression. Monitor for bradycardia and hypotension.

Titration Principles

In mechanically ventilated patients: Titrate to CPOT <3. Do not use a fixed infusion dose without regular reassessment.
In spontaneously breathing patients: NRS ≤3. Reassess every 4 hours.
Daily sedation interruption (DSI) with concurrent pain assessment during the "window" is mandated by international guidelines — but ensure analgesic coverage is maintained during and after DSI.

When to Escalate / When to Watch

Escalate if:

CPOT ≥3 or NRS >6 despite optimised multimodal analgesia

Haemodynamic instability (tachycardia, hypertension) in context of high behavioural pain scores

Patient is requiring >2 analgesic rescue doses per shift

Signs of opioid inadequacy: patient is distressing, desynchronising with ventilator, actively resisting care

Watch and reassess if:

CPOT 3–4 with single-agent therapy — implement multimodal stack before escalating opioids

Post-procedural pain likely to be transient (<30 minutes) — give short-acting agent and monitor

Suspected OIH — reduce opioid, add ketamine, reassess

De-escalate when:

CPOT consistently <3 for >12–24 hours

Patient is tolerating oral medications — transition to oral opioids with overlap

Ready for structured opioid weaning protocol (≥5 days on infusion)

Memorable Summary: The A-PAIN Framework

Letter	Domain	Key Action
A	Assess First	CPOT / BPS for non-verbal; NRS for verbal. Every shift. Every round.
P	Pain Before Sedation	Analgesia-first (analgosedation). Never sedate an unanalgesed patient.
A	Anticipate Procedure	Pre-medicate 15 min before every painful procedure.
I	Individualise & Rotate	Choose opioid based on renal function. Rotate if OIH suspected.
N	Non-opioid Stack	Paracetamol + ketamine + regional techniques. Opioids are one layer, not all layers.

Mnemonic: STOP Pain S — Score it (CPOT/NRS) T — Treat it (multimodal, not opioid-only) O — Observe for side effects (respiratory depression, OIH, withdrawal) P — Plan the wean (structured taper, not abrupt cessation)

References (Vancouver Style)

Devlin JW, Skrobik Y, Gélinas C, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018;46(9):e825–e873.
Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.
Gélinas C, Fillion L, Puntillo KA, et al. Validation of the Critical-Care Pain Observation Tool in adult patients. Am J Crit Care. 2006;15(4):420–427.
Chanques G, Viel E, Constantin JM, et al. The measurement of pain in intensive care unit: Comparison of 5 self-report intensity-rating scales. Pain. 2010;151(3):711–721.
Olsen BF, Rustøen T, Sandvik L, et al. Prevalence of pain in intensive care unit patients: Linked to patient and intensive care factors. Nurs Crit Care. 2016;21(6):364–372.
Shehabi Y, Howe BD, Bellomo R, et al. Early sedation with dexmedetomidine in critically ill patients (SPICE III): A randomised controlled trial. Lancet. 2019;394(10208):1537–1548.
Peng K, Liu HY, Liu SL, et al. Ketamine as an adjunct to intravenous patient-controlled analgesia following hip arthroplasty: A systematic review and meta-analysis. Pain Pract. 2022;22(2):175–187.
Grape S, Kirkham KR, Frauenknecht J, et al. Intra-operative analgesia with remifentanil vs. dexmedetomidine: A systematic review and meta-analysis with trial sequential analysis. Anaesthesia. 2019;74(6):793–800.
Weinbroum AA. Non-opioid IV adjuvants in the perioperative period: Pharmacological and clinical aspects of ketamine and gabapentinoids. Pharmacol Res. 2012;65(4):411–429.
Gélinas C, Chanques G, Puntillo K. In pursuit of pain: Recent advances and future directions in pain assessment in the ICU. Curr Opin Crit Care. 2014;20(2):131–137.
Olkowski BF, Shah SO. Early Mobilization in the Neuro-ICU: How Far Can We Go? Neurocrit Care. 2017;27(1):141–150.
Puntillo K, Arai SR, Cooper BA, et al. A randomized clinical trial of an intervention to relieve thirst and dry mouth in intensive care unit patients. Intensive Care Med. 2014;40(9):1295–1302.
Moline J, Temkin-Greener H. ICU pain management: Time to embrace multimodal analgesia. J Crit Care. 2021;62:250–254.
Blaudszun G, Lysakowski C, Elia N, Tramèr MR. Effect of systemic alpha2 agonists on postoperative morphine consumption and pain intensity: Systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2012;116(6):1312–1322.
Wick EC, Grant MC, Wu CL. Postoperative multimodal analgesia pain management with nonopioid analgesics and techniques: A review. JAMA Surg. 2017;152(7):691–697.

Correspondence: Author available for postgraduate teaching sessions and CME programme collaboration. Views expressed represent the author's academic interpretation of current evidence; clinical decisions should be individualised.

Word count: ~2,200

learningmedicine

Thursday, April 16, 2026